THDB(600867)
Search documents
晚间公告|11月6日这些公告有看头
Di Yi Cai Jing· 2025-11-06 10:17
Corporate Governance - China Aluminum announced the election of He Wenjian as chairman and the appointment of Zhang Ruizhong as general manager, effective immediately [3] - Jiang Guiting, the actual controller and chairman of Jingjin Equipment, has had his detention lifted, allowing him to resume his duties [8] - Biao Bang Co. has terminated its plans for a change in control, with stock resuming trading [7] Industry Developments - Jiangbolong reported that its self-developed main control chip deployment has exceeded 100 million units, with rapid growth expected [4] - Asia Pacific Pharmaceutical received a notice of disapproval for its consistency evaluation application for a drug, which will not significantly impact its current performance [5] - Fuxiang Pharmaceutical successfully passed a cGMP inspection by the FDA, marking its third successful inspection [6] - Huahai Pharmaceutical's subsidiary passed an FDA inspection, enhancing its international market capabilities [13] Financial Performance - Daqin Railway reported a cargo transport volume of 32.51 million tons in October 2025, a year-on-year decrease of 4.7% [18] - Jingji Zhino achieved sales revenue of 317 million yuan from selling 233,300 pigs in October 2025 [19] - Baiyun Airport reported a passenger throughput of 7.64 million in October 2025, a year-on-year increase of 12.04% [20] - Dongfeng Motor's total vehicle production in October 2025 was 6,536 units, a year-on-year decrease of 23.40% [21] - Hongyang Real Estate reported a contract sales amount of 202 million yuan in October 2025 [22] Shareholder Actions - Xintonglian announced that a shareholder plans to reduce its stake by up to 3% [24] - Tonghua Dongbao conducted its first share buyback, acquiring 143,500 shares for 1.29 million yuan [25] - Guoci Materials plans to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 30 yuan per share [26] Project Wins - Dayu Water-saving announced a pre-bid win for a 310 million yuan water conservancy project in Hainan [28] - Zhongjian Technology signed a significant sales contract worth 563 million yuan [29] - Longjian Co. won a project bid worth 441 million yuan for road construction in Heilongjiang [30] - Chongqing Construction's subsidiary won a project bid worth 781 million yuan for a residential project in Chongqing [31]
通化东宝:首次回购约14万股
Mei Ri Jing Ji Xin Wen· 2025-11-06 09:43
Group 1 - Company announced a share repurchase of approximately 140,000 shares, representing 0.01% of the total share capital, at a price range of 9 CNY per share, with a total transaction amount of approximately 1.29 million CNY [1] - For the first half of 2025, the company's revenue composition was 98.59% from the pharmaceutical industry, 1.27% from other businesses, and 0.14% from the real estate sector [1] - The current market capitalization of the company is 17.7 billion CNY [1]
通化东宝(600867.SH):首次回购14.35万股公司股份
Ge Long Hui A P P· 2025-11-06 08:51
Group 1 - The company, Tonghua Dongbao (600867.SH), announced its first share repurchase on November 6, 2025, through centralized bidding [1] - A total of 143,500 shares were repurchased, accounting for 0.01% of the company's current total share capital [1] - The highest and lowest transaction prices for the repurchase were both 9.00 yuan per share, with a total transaction amount of 1.2915 million yuan (excluding transaction fees) [1]
通化东宝:首次回购0.01%公司股份 耗资129.15万元
Xin Lang Cai Jing· 2025-11-06 08:25
通化东宝公告,公司于2025年11月6日首次通过集中竞价交易方式回购公司股份,累计回购股数为14.35 万股,占公司总股本的0.01%,累计回购金额为129.15万元,实际回购价格为9元/股。此次回购将用于 员工持股计划或股权激励。 ...
通化东宝跌2.05%,成交额4.48亿元,主力资金净流出1100.74万元
Xin Lang Cai Jing· 2025-11-04 06:34
Company Overview - Tonghua Dongbao Pharmaceutical Co., Ltd. is located in Tonghua County, Jilin Province, established on December 28, 1992, and listed on August 24, 1994 [1] - The company's main business includes hard capsule preparations, tablets (including hormone types), granules, small-volume injections, raw materials (recombinant human insulin), and biological engineering products (recombinant human insulin injection) [1] Financial Performance - For the period from January to September 2025, Tonghua Dongbao achieved operating revenue of 2.18 billion yuan, a year-on-year increase of 50.55% [2] - The net profit attributable to the parent company was 1.20 billion yuan, showing a significant year-on-year growth of 1911.35% [2] Stock Market Activity - As of November 4, the stock price of Tonghua Dongbao was 9.08 yuan per share, with a market capitalization of 17.78 billion yuan [1] - The stock has increased by 16.23% year-to-date, with a 2.02% rise over the last five trading days and a 9.79% increase over the last 20 days [1] Shareholder Information - As of September 30, 2025, the number of shareholders was 82,100, a decrease of 5.08% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 15.84 million shares [3] Dividend Distribution - Since its A-share listing, Tonghua Dongbao has distributed a total of 5.51 billion yuan in dividends, with 1.48 billion yuan distributed in the last three years [3]
通化东宝药业股份有限公司2025年第三次临时股东会决议公告
Shang Hai Zheng Quan Bao· 2025-11-03 18:20
Core Points - The company held its third extraordinary general meeting of shareholders on November 3, 2025, with no resolutions being rejected [2][5] - The meeting was convened by the board of directors and chaired by Chairman Li Jiahong, utilizing a combination of on-site and online voting methods [2][5] Group 1: Meeting Details - The meeting was attended by all nine current directors and three supervisors, with the presence of senior management [3][4] - Several governance-related proposals were passed, including the cancellation of the supervisory board and amendments to the company's articles of association [3][4] - The voting results were deemed legal and valid, in compliance with relevant laws and regulations [5] Group 2: Board Changes - Director Zhang Guodong submitted a resignation letter due to internal work adjustments but will continue as the company's deputy general manager [8][9] - Zhang Guodong was elected as a representative director of the employee board during the ninth fourth employee representative conference held on November 3, 2025 [8][10] - His resignation does not affect the minimum number of board members required by law and will not disrupt the normal operations of the board [9][10] Group 3: Director Profile - Zhang Guodong, born in August 1976, holds a bachelor's degree in clinical medicine and an MBA [12] - He has a history of working in the pharmaceutical industry, including roles at Federal Pharmaceuticals and Eli Lilly, before joining the company in 2005 [12] - As of the announcement date, he holds 264,120 shares of the company, representing 0.01% of the total share capital [12]
通化东宝:选举张国栋先生为公司第十一届董事会职工代表董事
Zheng Quan Ri Bao· 2025-11-03 12:14
Core Viewpoint - Tonghua Dongbao announced the election of Mr. Zhang Guodong as the employee representative director for the 11th board of directors during the 4th employee representative assembly scheduled for November 3, 2025 [2] Group 1 - The 9th Fourth Employee Representative Assembly will be held on November 3, 2025 [2] - Mr. Zhang Guodong has been elected as the employee representative director [2]
通化东宝(600867) - 通化东宝关于公司董事辞职暨选举职工代表董事的公告
2025-11-03 09:30
证券代码:600867 证券简称:通化东宝 公告编号:2025-077 通化东宝药业股份有限公司 关于公司董事辞职暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 通化东宝药业股份有限公司(以下简称"公司")董事会近日收到董事张国 栋先生递交的书面辞职报告,因公司内部工作调整,张国栋先生申请辞去公司董 事的职务。辞职后,张国栋先生继续担任公司副总经理职务。 2025 年 11 月 3 日,公司召开第九届第四次职工代表大会,同意选举张国栋 先生为公司第十一届董事会职工代表董事,任期自公司职工代表大会选举之日起 至公司第十一届董事会任期届满之日止。 一、董事辞职情况 (一) 基本情况 | 姓名 | 离任 职务 | 离任时间 | 原定任期到期日 | 离任 原因 | 是否继续 在上市公 司及其控 股子公司 任职 | 具体职务 | 是否存在 未履行完 毕的公开 承诺 | | --- | --- | --- | --- | --- | --- | --- | --- | | 张国栋 | 董事 | 2 ...
通化东宝(600867) - 吉林秉责律师事务所关于通化东宝2025年第三次临时股东会的法律意见书
2025-11-03 09:30
吉林秉责律师事务所 本次股东会由公司董事会召集,会议召开方式为现场投票与网络投票相结合 的方式。 1 关于通化东宝药业股份有限公司 二 0 二五年第三次临时股东会的法律意见书 致:通化东宝药业股份有限公司 根据《中华人民共和国证券法》(以下简称"证券法")、《中华人民共和国 公司法》(以下简称《公司法》)、《上市公司股东会规则》(以下简称《股东会规 则》)和《通化东宝药业股份有限公司章程》(以下简称《公司章程》)的有关规 定,吉林秉责律师事务所(以下简称"本所")接受了通化东宝药业股份有限公 司(以下简称"公司")的委托,担任公司 2025 年第三次临时股东会(以下简称 "本次股东会")特聘专项法律顾问并出具法律意见书。 本法律意见书仅供公司为本次股东会之目的而使用,不得用于其他任何目 的。本所同意公司将本法律意见书作为本次股东会的公告材料,随其他需要公告 的信息一起向公众披露,并依法对本所在其中发表的法律意见承担责任。 为出具本法律意见书,本所指派郭淑芬、商家碧律师出席了公司于 2025 年 11 月 3 日上午 10 时在公司会议室召开的本次股东会,审查了公司提供的与召开 本次股东会有关的文件和资料,并进 ...
通化东宝(600867) - 通化东宝2025年第三次临时股东会决议公告
2025-11-03 09:30
证券代码:600867 证券简称:通化东宝 公告编号:2025-076 通化东宝药业股份有限公司 重要内容提示: 本次会议是否有否决议案:无 一、 会议召开和出席情况 (一)股东会召开的时间:2025 年 11 月 3 日 (二)股东会召开的地点:公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况: | 1、出席会议的股东和代理人人数 | 599 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数(股) | 881,399,412 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例(%) | 45.1362 | 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 (四)表决方式是否符合《公司法》及《公司章程》的规定,大会主持情况等。 本次会议由公司董事会召集,公司董事长李佳鸿先生主持会议。会议采用现 场投票和网络投票相结合的表决方式。本次会议的召集、召开符合《公司法》和 《公司章程》的有关规定。 1 (五) ...